[A22-86] Empagliflozin (heart failure and preserved ejection fraction) - Addendum to Commission A22-39
Last updated 15.09.2022
Project no.:
A22-86
Commission:
Commission awarded on 09.08.2022 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Heart and circulation
Indication:
Adults with symptomatic chronic heart failure with preserved ejection fraction
Result of dossier assessment:
Unchanged after addendum:
- Without type 2 diabetes mellitus and without chronic kidney disease or with/without type 2 diabetes mellitus and with chronic kidney disease: hint of non-quantifiable added benefit
- With type 2 diabetes mellitus and without chronic kidney disease: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A22-39 | Empagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2022-09-15 A G-BA decision was published.